Pharmacotherapeutic group: Alpha-adrenoblocker
ATX code: C02CA
Proroxan has hypotensive and antipruritic effects. It blocks postsynaptic alpha1- and presynaptic alpha2-adrenoreceptors regardless of their localization. It has a peripheral and central effect. It decreases the sensitivity of adrenoreceptors to adrenaline by changing the permeability of cell membranes. Reduces the intensity of stimulation of hypothalamic structures by reducing the release of tropic hormones of peripheral gland hormones. Weakens the transmission of adrenergic vasoconstrictor impulses eliminates spasm and dilates peripheral vessels especially arterioles and precapillaries. Improves blood supply to the muscles of the skin and mucous membranes. Inhibits excitability of diencephalic brain structures and regulates sympathoadrenal system tone.
– Somatoform vegetative dysfunction of the sympathoadrenal type, including increased blood pressure (as symptomatic treatment in combination therapy);
– allergic dermatitis (as symptomatic treatment in combination therapy to relieve itching).
1 tablet contains:
the active ingredient:
proxan hydrochloride 0.015 g;
lactose monohydrate 0.078 g,
potato starch 0.005 g,
talc 0.001 g,
magnesium stearate 0.001 g.
How to take, the dosage
In somatoform vegetative dysfunction of the sympathoadrenal type in the complex therapy is prescribed 15-30 mg (1-2 tablets) orally 2-3 times a day. The duration of treatment is determined by the attending physician.
In case of allergic dermatitis in complex therapy it is recommended to be prescribed 15-30 mg (1-2 tablets) orally before sleep. The duration of treatment is determined by the attending physician.
The concomitant use of proxane and adrenaline may lead to a decrease in the effectiveness of the latter (development of a depressor effect instead of a pressor effect). Concomitant use with hypotensive agents leads to mutual enhancement of the effect of blood pressure reduction.
It enhances the effect of neuroleptics (phenothiazine derivatives butyrophenone diphenylbutylpiperidine thioxanthene).
With co-administration with novocainamide there may be a decrease in the stroke volume of the heart.
Particulars of action of the drug at the first dose:
The first dose of the drug may cause a sharp decrease in blood pressure fainting headache weakness palpitations and deterioration of the subjective state (“first-dose phenomenon”) which is not a reason to cancel the drug as this effect disappears when taking it again. Drowsiness is also noted, with the sensation of numbness of the tongue passing quickly. In addition, it is recommended to monitor the blood glucose concentration due to a possible increase in the level of endogenous insulin. In this regard, it is necessary to begin treatment under medical supervision with the minimum effective dose and to observe bed rest for 6-8 hours after taking the drug.
Influence on ability to drive motor vehicle and motor vehicle:
When taking the drug, it is not recommended to drive vehicles and perform other potentially dangerous activities requiring increased concentration and quick psychomotor reactions.
Round biconvex tablets are white or white with a yellowish tint.
– Hypersensitivity to the active substance and excipients of the drug;
– Coronary heart disease (functional class II-IV);
– circulatory insufficiency degree II-III;
– arterial hypotension;
– cardiogenic shock;
– myocardial infarction;
– significant atherosclerosis;
– significant cerebrovascular insufficiency (including a history of strokes and transient ischemic attacks);
– age less than 18 years (efficacy and safety not established);
– lactase deficiency lactose intolerance glucose-galactose malabsorption syndrome.
Elderly age coronary heart disease arrhythmia peptic ulcer disease.
Control of blood glucose concentration is recommended (increased endogenous insulin levels are possible).
The incidence of adverse reactions is given according to the World Health Organization (WHO) classification: very frequently – more than 1/10 frequently – more than 1/100 and less than 1/10 infrequently – more than 1/1000 and less than 1/100 rarely – more than 1/10000 and less than 1/1000 very rarely – less than 1/10000; frequency is unknown (according to available data it is impossible to determine the frequency of development).
Cardiovascular system disorders: frequency unknown – bradycardia arterial hypotension occurrence of angina attacks in predisposed patients orthostatic hypotension arrhythmia dizziness skin hyperemia nasal congestion.
Gastrointestinal tract: frequency unknown – diarrhea increased secretion of hydrochloric acid in the stomach.
Skin disorders: frequency unknown – allergic reactions.
If any of the side effects listed in the instructions worsen, or if you notice any other side effects not listed in the instructions, tell your doctor.
Symptoms: bradycardia sharp decrease in blood pressure orthostatic collapse.
Treatment: symptomatic aimed at maintenance of vital functions.
Vegetrox® is contraindicated in pregnancy and during breastfeeding due to insufficient data on efficacy and safety.
3 years. Do not use after the expiration date.
|Conditions of storage|
Store in the dark place at a temperature not exceeding 30°C. Store out of the reach of children.
PharmVilar NGO, Russia
Buy Vegetrox, tablets 15 mg 10 pcs with delivery to USA, UK, Europe and over 120 other countries.